- Home
- IMAB vs APLT Comparison
IMAB vs APLT Comparison
Compare IMAB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- APLT
- Stock Information
- Founded
- IMAB 2014
- APLT 2016
- Country
- IMAB United States
- APLT United States
- Employees
- IMAB N/A
- APLT N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- APLT Health Care
- Exchange
- IMAB Nasdaq
- APLT Nasdaq
- Market Cap
- IMAB 79.9M
- APLT 80.3M
- IPO Year
- IMAB 2020
- APLT 2019
- Fundamental
- Price
- IMAB $0.97
- APLT $0.53
- Analyst Decision
- IMAB Strong Buy
- APLT Buy
- Analyst Count
- IMAB 3
- APLT 7
- Target Price
- IMAB $8.00
- APLT $6.10
- AVG Volume (30 Days)
- IMAB 270.1K
- APLT 3.0M
- Earning Date
- IMAB 03-13-2025
- APLT 03-05-2025
- Dividend Yield
- IMAB N/A
- APLT N/A
- EPS Growth
- IMAB N/A
- APLT N/A
- EPS
- IMAB N/A
- APLT N/A
- Revenue
- IMAB $569,464.00
- APLT N/A
- Revenue This Year
- IMAB N/A
- APLT N/A
- Revenue Next Year
- IMAB N/A
- APLT $2,622.90
- P/E Ratio
- IMAB N/A
- APLT N/A
- Revenue Growth
- IMAB N/A
- APLT N/A
- 52 Week Low
- IMAB $0.84
- APLT $0.53
- 52 Week High
- IMAB $2.00
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- IMAB 46.51
- APLT 29.75
- Support Level
- IMAB $0.96
- APLT $0.54
- Resistance Level
- IMAB $1.04
- APLT $0.70
- Average True Range (ATR)
- IMAB 0.05
- APLT 0.06
- MACD
- IMAB -0.00
- APLT 0.06
- Stochastic Oscillator
- IMAB 36.36
- APLT 0.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.